miR-22 inhibited multiple oncogenes, including CREB-regulated transcription coactivator 1 (CRTC1), homeobox (HOXA)7, FLT3 and MYCBP (a MYC-binding protein), and consequently the CREB and MYC pathways, leading to the inhibition of leukemia progression in vivo (40). This evidence concerns the gene MYCBP and leukemia.